3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trialJosé Manuel Pérez-García,Javier Cortés,Manuel Ruiz-Borrego,Marco Colleoni,Agostina Stradella,Begoña Bermejo,Florence Dalenc,Santiago Escrivá-de-Romaní, Lourdes Calvo Martínez,Nuria Ribelles,Frederik Marmé, Alfonso Cortés, Cinta Albacar,Geraldine Gebhart,Aleix Prat,Khaldoun Kerrou,Peter Schmid,Sofia Braga,Serena Di Cosimo,Maria Gion,Gabriele Antonarelli,Crina Popa, Emilia Szostak,Daniel Alcalá-López, Petra Gener, Jose Rodríguez-Morató,Leonardo Mina,Miguel Sampayo-Cordero,Antonio Llombart-CussacThe Lancet（2024）引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
